美国食品药品监督管理局批准摘要:法姆-曲妥珠单抗德鲁替康-nxki用于人表皮生长因子受体2低表达不可切除或转移性乳腺癌
美国食品药品监督管理局基于DESTINY-Breast04试验批准法姆-曲妥珠单抗德鲁替康-nxki(T-DXd)用于既往接受过化疗的HER2低表达不可切除或转移性乳腺癌成人患者。该III期随机开放标签多中心试验纳入557例患者,T-DXd组在激素受体阳性队列和意向治疗人群的无进展生存期和总生存期均显著优于医生选择的化疗。
要点
- T-DXd获批用于HER2低表达(IHC 1+或IHC 2+/ISH-)不可切除或转移性乳腺癌成人患者。
- DESTINY-Breast04试验中T-DXd组HR+队列PFS的HR为0.51(95%CI 0.40-0.64;P<.0001)。
- T-DXd安全性特征与既往已批准适应症一致,未观察到新的安全信号。
核心结论
- T-DXd在HER2低表达转移性乳腺癌中的获批基于DESTINY-Breast04试验中观察到的具有统计学显著性和临床意义的PFS和OS改善,是首个专门针对HER2低表达转移性乳腺癌获批的治疗。
研究设计与样本
- 批准基于DESTINY-Breast04,一项III期、随机、开放标签、多中心试验,纳入不可切除或转移性HER2低表达乳腺癌患者,HER2状态由中心实验室确定。
- 共557例患者按2:1随机分配至T-DXd 5.4 mg/kg静脉给药每3周一次(n=373)或医生选择的化疗(n=184)。
主要发现
- 主要疗效终点为盲法独立中心评审评估的PFS,在激素受体阳性(HR+)队列(N=494)中达到,估计HR为0.51(95%CI 0.40-0.64;P<.0001)。
- 意向治疗人群PFS的HR为0.50(95%CI 0.40-0.63;P<.0001)。
- HR+队列OS的HR为0.64(95%CI 0.48-0.86;P=.0028)。
- 意向治疗人群OS的HR为0.64(95%CI 0.49-0.84;P=.0010)。
- T-DXd的安全性特征与既往已批准适应症一致,在该研究人群中未观察到新的安全信号。
关键数值与推荐
- FDA批准T-DXd用于成人不可切除或转移性HER2低表达(免疫组化1+或免疫组化2+/原位杂交-)乳腺癌患者,且既往在转移阶段接受过化疗或在完成辅助化疗期间或完成后6个月内出现疾病复发。
- T-DXd给药方案为5.4 mg/kg静脉给药每3周一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The US Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (DS-8201a, T-DXd) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry 1 + or immunohistochemistry 2+/in situ hybridization-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. PATIENTS AND METHODS: Approval was based on DESTINY-Breast04, a phase III, randomized, open-label, multicenter trial in patients with unresectable or metastatic HER2-low breast cancer, determined at a central laboratory. A total of 557 patients were randomly assigned (2:1) to receive either T-DXd 5.4 mg/kg intravenously once every 3 weeks (n = 373) or physicians' choice of chemotherapy (n = 184). RESULTS: The study met its primary efficacy end point of progression-free survival (PFS) by blinded independent central review assessment in the hormone receptor-positive (HR+) cohort (N = 494) with an estimated hazard ratio (HR) of 0.51(95% CI, 0.40 to 0.64; P < .0001). Key secondary end points were also met, including PFS in the intent-to-treat population with an HR of 0.50 (95% CI, 0.40 to 0.63; P < .0001), overall survival (OS) in the HR+ cohort with an HR of 0.64 (95% CI, 0.48 to 0.86; P = .0028) and OS in the intent-to-treat with an HR of 0.64 (95% CI, 0.49 to 0.84; P = .0010). The safety profile of T-DXd was consistent with previously approved indications, and no new safety signals were observed in this study population. CONCLUSION: The approval of T-DXd in HER2-low metastatic breast cancer was based on statistically significant and clinically meaningful PFS and OS improvements observed in the DESTINY-Breast04 trial and represents the first approved therapy specifically for the treatment of HER2-low metastatic breast cancer.
引用
- Narayan P, Dilawari A, Osgood C, et al. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. J Clin Oncol. 2023. PMID: 36780610. doi:10.1200/JCO.22.02447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。